Gennex Laboratories
add_icon

Gennex Laboratories

11.20
-0.40
(-3.45%)
Market Cap
272.08 Cr
PE Ratio
14.32
Volume
9,69,373.00
Day High - Low
11.60 - 10.91
52W High-Low
17.25 - 10.84
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
272.08 Cr
EPS
0.80
PE Ratio
14.32
PB Ratio
1.32
Book Value
8.79
EBITDA
27.10
Dividend Yield
0.00 %
Industry
Healthcare
Return on Equity
9.31
Debt to Equity
0.04
Forecast For
Actual

Company News

View All News
Caret
neutral
Gennex Laboratories Limited published its Q3 FY26 unaudited financial results in newspapers as per regulatory requirements, with results approved by the Board on February 14, 2026.
neutral
Ms. Shilpa Bung resigned as Non-Executive Independent Women Director of Gennex Laboratories with immediate effect on February 14, 2026, citing new role as CS Hyderabad Chapter Chairperson.
positive
Gennex Laboratories reported consolidated net profit of ₹599.22 lakhs for Q3FY26, up 18.3% YoY. Revenue from operations grew 7.1% to ₹4,036.64 lakhs with strong performance in bulk drugs.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,764.20
#1 4,23,290.68
37.91
#1 54,729.00
9.71
#1 10,980
16.07
66.93
6,395.50
1,69,780.43
66.98
9,712.00
18.67
2,191
-1.02
58.33
4,418.90
1,49,555.66
65.53
11,539.40
6.99
1,911
26.24
75.24
1,306.50
1,09,044.46
19.64
33,741.20
16.73
5,725
-15.28
64.85
1,346.10
1,08,734.16
23.63
28,409.50
7.12
5,291
-57.18
46.84
2,292.20
1,04,707.42
22.04
22,909.50
13.74
3,306
#1 37.44
69.01
919.65
92,538.31
#1 18.11
23,511.00
18.55
4,615
-0.32
56.15
2,155.70
88,988.39
47.01
12,744.20
#1 20.90
2,007
7.65
57.55
1,211.50
70,364.12
19.41
32,345.60
9.43
3,484
7.59
57.08
5,625.00
67,255.31
27.13
13,458.30
3.70
2,216
1.90
51.41
Growth Rate
Revenue Growth
61.90 %
Net Income Growth
37.12 %
Cash Flow Change
76.87 %
ROE
24.63 %
ROCE
14.53 %
EBITDA Margin (Avg.)
-23.56 %

Quarterly Financial Results

Quarterly Financials
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Revenue
8
11
12
14
10
11
15
21
16
14
15
12
13
15
15
16
10
14
17
20
14
19
14
19
17
18
19
34
31
32
38
44
37
37
40
Expenses
7
10
11
14
9
10
14
19
15
13
14
11
12
14
14
14
9
12
15
19
13
18
13
17
11
12
17
29
24
26
33
39
29
32
35
EBITDA
1
1
1
1
1
1
1
2
2
1
1
1
1
2
2
3
2
2
1
1
1
1
1
1
5
5
3
4
7
6
5
6
7
6
6
Operating Profit %
9 %
8 %
7 %
-1 %
8 %
7 %
8 %
7 %
8 %
7 %
4 %
5 %
6 %
10 %
11 %
16 %
16 %
13 %
7 %
4 %
6 %
7 %
8 %
7 %
31 %
29 %
13 %
13 %
15 %
18 %
13 %
5 %
15 %
15 %
14 %
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
0
0
1
1
1
1
1
1
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
0
1
1
1
1
1
Profit Before Tax
0
0
1
0
1
1
1
1
1
1
0
0
1
1
2
2
1
2
1
1
1
1
2
3
4
4
4
5
6
6
6
4
6
6
7
Tax
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
1
1
1
1
Net Profit
0
0
0
-0
1
1
1
0
1
1
0
0
0
1
1
2
1
1
1
1
1
1
1
2
3
3
3
5
5
5
5
3
5
6
6
EPS in ₹
0.03
0.03
0.02
-0.02
0.03
0.04
0.07
0.02
0.06
0.04
0.02
0.02
0.03
0.07
0.10
0.15
0.08
0.09
0.06
0.10
0.06
0.08
0.07
0.19
0.16
0.16
0.16
0.16
0.19
0.21
0.22
0.14
0.22
0.21
0.22

Balance Sheet

Balance Sheet
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
49
51
52
57
59
68
132
230
256
Fixed Assets
16
16
16
15
14
14
74
56
60
Current Assets
26
28
29
35
38
47
49
162
181
Capital Work in Progress
0
0
0
0
0
0
0
2
5
Investments
7
7
7
7
7
7
0
0
0
Other Assets
27
28
29
35
38
48
59
172
191
Total Liabilities
49
51
52
57
59
68
132
230
256
Current Liabilities
17
18
17
21
19
24
30
40
45
Non Current Liabilities
1
1
1
0
0
0
16
13
17
Total Equity
31
32
34
36
40
44
87
177
195
Reserve & Surplus
18
19
21
23
27
31
62
142
158
Share Capital
13
13
13
13
13
13
18
23
23

Cash Flow

Cash Flow
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
-0
0
2
-2
0
8
6
46
-5
Investing Activities
-1
-1
-1
-0
0
-3
-38
19
1
Operating Activities
-0
3
2
-2
-1
12
24
-47
-11
Financing Activities
1
-2
1
-0
2
-2
21
74
5

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Aug 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Feb 2024
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Jul 2025
Sept 2025
Dec 2025
Promoter
22.05 %
22.05 %
22.05 %
22.05 %
22.05 %
22.05 %
23.38 %
23.38 %
23.38 %
23.38 %
23.38 %
23.60 %
23.60 %
18.42 %
18.42 %
18.42 %
18.42 %
18.42 %
18.42 %
19.83 %
23.62 %
23.62 %
23.62 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
63.16 %
70.52 %
74.55 %
73.70 %
75.16 %
74.50 %
61.37 %
63.41 %
63.41 %
63.27 %
60.60 %
58.05 %
60.22 %
58.81 %
60.42 %
61.74 %
59.00 %
60.53 %
62.19 %
61.90 %
58.97 %
59.34 %
56.47 %
Others
14.79 %
7.43 %
3.40 %
4.25 %
2.79 %
3.45 %
15.25 %
13.21 %
13.21 %
13.35 %
16.02 %
18.34 %
16.17 %
22.78 %
21.16 %
19.85 %
22.59 %
21.05 %
19.39 %
18.28 %
17.41 %
17.04 %
19.91 %
No of Share Holders
20,806
36,243
46,380
50,052
56,689
57,877
57,603
59,172
58,248
55,609
52,981
50,988
69,723
69,750
83,996
87,820
90,236
92,506
92,326
91,183
91,183
90,320
86,306

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
22 Jul 2022 RIGHTS Rights
1:2
21 Jul 2022 6.66 6.82
30 Dec 2023 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
30 Dec 2023 16.10 16.81
30 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
30 Sept 2024 18.56 23.62
14 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Nov 2024 20.41 19.21
14 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Feb 2025 14.47 13.50
30 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
30 May 2025 13.11 13.79
14 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Aug 2025 13.00 12.45
30 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
30 Sept 2025 11.48 11.43
14 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Nov 2025 15.46 15.67
14 Feb 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Feb 2026 12.47 12.26

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication8 days ago
Intimation Of Reconstitution Of Audit Committee Stakeholders Relationship Committee And Nomination And Remuneration Committee Under Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirement) Regulations 2015Feb 14, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 14, 2026
Announcement under Regulation 30 (LODR)-Resignation of DirectorFeb 14, 2026
Quarter And Nine Months Ended December 31 2025Feb 14, 2026
Board Meeting Outcome for Board Meeting Outcome For Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025Feb 14, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 09, 2026
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Nine Months Ended December 31 2025Feb 05, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 12, 2026
Closure of Trading WindowDec 16, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 17, 2025
Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025Nov 14, 2025
Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025Nov 14, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 06, 2025
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended September 30 2025Nov 04, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 13, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportOct 01, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 30, 2025
Closure of Trading WindowSep 23, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 08, 2025
Reg. 34 (1) Annual Report.Sep 08, 2025
Intimation Of Book Closure For AGMSep 04, 2025
Board Meeting Outcome for For Meeting Held On 04Th September 2025 For Approval Of Board Reports And AGM Related AgendaSep 04, 2025
Board Meeting Intimation for Fixing Date Time And Venue Of 40Th AGM Of The CompanyAug 26, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 18, 2025
Unaudited Financial Results For The Quarter Ended June 30 2025Aug 14, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Of Gennex Laboratories Limited Held On August 14 2025 For Unaudited Financial Results Of First Quarter Ended June 30 2025 Aug 14, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 07, 2025
Approval Of Products From Drugs Control Administration Government Of Andhra Pradesh For Our Subsidiary Company Deccan Remedies LimitedJul 28, 2025
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30 2025Jul 28, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 24, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 14, 2025
Board Meeting Outcome for Board Meeting Held On July 08 2025 For Conversion Of 55 Lakhs Warrants Into Equity SharesJul 08, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 07, 2025
Board Meeting Outcome for Board Meeting Held On July 04 2025 For Conversion Of 60 Lacs Warrants Into Equity SharesJul 04, 2025
Closure of Trading WindowJun 23, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Of Gennex Laboratories Limited Held On June 04 2025 For Conversion Of Warrants Into Equity SharesJun 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 02, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2025
Appointment Of Mr. Sandeep Kumar Daga As Additional (Non-Executive Non Independent) Director Of The CompanyMay 30, 2025
Announcement under Regulation 30 (LODR)-Resignation of DirectorMay 30, 2025
Audited Financial Results For The Year Ended March 31 2025May 30, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On May 30 2025 For Audited Financial Result For The Quarter And Year Ending March 31 2025May 30, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 22, 2025
Approval Of Additional Products From Drugs Control Administration Government Of Andhra Pradesh For Our Subsidiary Company Deccan Remedies LimitedMay 22, 2025
Board Meeting Intimation for For Consideration And Approval Of Audited Financial Results (Standalone And Consolidated) For The Quarter And Year Ended March 31 2025May 20, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 22, 2025
Closure of Trading WindowMar 26, 2025
Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.Mar 24, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Mar 24, 2025

Technical Indicators

RSI(14)
Neutral
34.29
ATR(14)
Less Volatile
0.54
STOCH(9,6)
Oversold
15.93
STOCH RSI(14)
Oversold
2.36
MACD(12,26)
Bearish
-0.02
ADX(14)
Strong Trend
32.82
UO(9)
Bearish
31.97
ROC(12)
Downtrend And Accelerating
-4.53
WillR(14)
Oversold
-88.28